Concepedia

Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders

Christine Lebrun‐Frénay, Mikaël Cohen, Maria Alessandra Rosenthal‐Allieri, Saskia Bresch, Sylvia Benzaken, Romain Marignier, Barbara Seitz‐Polski, Michel Ticchioni

Neurology and Therapy · 2018 · 38 citations · 27 references

DOIFull text

Open access

Abstract

In contrast to total CD19+ cell, detected with the routine technique, CD19+ CD27+ memory B cells are a reliable marker for biological relapse and allow a decrease in the frequency of infusions.

References

27

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al. · Neurology · 2015 · 4.3K citations · Full text

, , +13

New Multiple Sclerosis Phenotypic Classification

Fred Lublin · European Neurology · 2014 · 4.2K citations

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

Vanda A. Lennon, Dean M. Wingerchuk, Thomas J. Kryzer et al. · The Lancet · 2004 · 3.2K citations

, , +12

Revised diagnostic criteria for neuromyelitis optica

Dean M. Wingerchuk, Vanda A. Lennon, Sean J. Pittock et al. · Neurology · 2006 · 2.6K citations · Full text

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold et al. · New England Journal of Medicine · 2008 · 2.4K citations · Full text